Treatment of liver and lung metastases from colorectal cancer;Behandling af lever- og lungemetastaser fra kolorektal cancer

Ugeskrift for Laeger

Volumn 167, Issue 45, 2005, Pages 4268-4272

  Burcharth, Flemming ^a   Jensen, Benny Vittrup ^b  

^a Kirurgisk Gastroenterologisk Afd D   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; LUNG METASTASIS; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL TIME; TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CATHETER ABLATION; COLORECTAL TUMOR; LIVER TUMOR; LUNG TUMOR; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 27744521735     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Topal B, Flamen P, Aerts R et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001;27:175-9.
2. Chau I, Allen MJ, Cunningham D et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004;22:1420-9.
3. Scheele J, Altendorf-Hofmann A, Grube T et al. Resection of colorectal liver metastases. Chirurg 2001;72:547-60.
4. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992;10:904-11.
5. Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-5.
6. Baden H, Andersen B. Survival of patients with untreated liver metastases from colorectal cancer. Scand J Gastroenterol 1975;10:221-3.
7. Pedersen IK, Burcharth F, Roikjaer O et al. Resection of liver metastases from colorectal cancer. Dis Colon Rectum 1994;37:1078-82.
8. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996;77:1254-62.
9. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
10. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25.
11. Adam R, Bismuth H, Castaing D et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997;225:51-60.
12. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476-87.
13. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
14. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
15. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537-41.
16. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
17. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
18. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
19. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
20. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-53.
21. Wein A, Riedel C, Kockerling F et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001;12:1721-7.
22. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
23. Rivoire M, de Cian F, Meeus P et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:2283-92.
24. Alberts SR, Donohue JH, Mahoney MR et al. Liver resection after 5-Fluorouracil, leucovorin and Oxaliplatin (FOLFOX4) for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) Phase II study. Proc Am Soc Clin Oncol 2003:1053.
25. Allen PJ, Kemeny N, Jarnagin W et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109-15.
26. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252-8.
27. Ducreux M, Ychou M, Laplanche A et al. Intra-arterial hepatic chemotherapy (IAHC) with Oxaliplatin (O) combined with intravenous treatment with 5-FU + Folinic Avid (FA) in hepatic metastases of colorectal cancer (HMCRC). Proc Am Soc Clin Oncol 2003:1115.
28. Ricke J, Hildebrandt B, Miersch A et al. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. J Vasc Interv Radiol 2004;15:825-33.
29. Kerr DJ, McArdle CS, Ledermann J et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361:368-73.
30. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.
31. Andre T, Boni C, Moimedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
32. Steinke K, King J, Glenn D et al. Radiofrequency ablation (RFA) of lung metastases from colorectal cancer (CRC)-one-year follow-up. Radiologe 2004;44:687-92.
33. Hohenberger P, Schlag PM, Gerneth T et al. Pre- and postoperative carcino-embryonic antigen determinations in hepatic resection for colorectal metastases. Ann Surg 1994;219:135-43.
34. Ohlsson B, Palsson B. Follow-up after colorectal cancer surgery. Acta Oncol 2003;42:816-26.
35. Borie F, Daures JP, Millat B et al. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg 2004;8:552-8.
36. Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 2000;355:395-9.
37. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cocrane review). I: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons.
38. Renehan AG, O'dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ 2004;328:81.
39. Secco GB, Fardelli R, Gianquinto D et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002;28:418-23.